Zenas BioPharma (ZBIO) Other Accumulated Expenses (2023 - 2026)

Zenas BioPharma's Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $936000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 143.75% year-over-year to $936000.0 in Q1 2026; TTM through Mar 2026 was $936000.0, a 143.75% increase from a year earlier, with the FY2025 full-year figure at $870000.0, up 249.4% from the prior year.
• Other Accumulated Expenses grew to $936000.0 in Q1 2026 per ZBIO's latest filing, from $870000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $936000.0 in Q1 2026 and bottomed at $106000.0 in Q4 2023.
• The 4-year median for Other Accumulated Expenses is $446000.0 (2025), against an average of $495625.0.
• Biggest YoY gain for Other Accumulated Expenses was 249.4% in 2025; the steepest drop was 74.7% in 2025.
• Year by year, Other Accumulated Expenses stood at $106000.0 in 2023, then surged by 134.91% to $249000.0 in 2024, then surged by 249.4% to $870000.0 in 2025, then gained by 7.59% to $936000.0 in 2026.
• Per Business Quant, the three latest ZBIO Other Accumulated Expenses figures stand at $936000.0 (Q1 2026), $870000.0 (Q4 2025), and $580000.0 (Q3 2025).